Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering's lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic ...
Libtayo (cemiplimab). The supply agreement supports the evaluation of Immuneering's lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS ...
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...
Treatment with THIO followed by cemiplimab (Libtayo®) has been generally well ... the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research ...
The two companies will carry out a phase 2 trial of Libtayo (cemiplimab) alongside BioNTech ... to or have relapsed after PD-1 drugs, and the costs of running it will be shared by the two ...
In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a ... its oncology pipeline to absorb the hit of lower-cost biosimilars reaching the market.